In a similar model for prostate cancer, the same drug mimicked the results of N-cadherin ablation in prostate cancer cells, reducing immunosuppression and enhancing tumor-infiltrating leukocyte-related therapy by modulating the expression of immune checkpoint inhibitors [44]. This evidence concerns the gene CDH2 and prostate carcinoma.